{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T03:24:16Z","timestamp":1772249056499,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12916-016-0610-x","type":"journal-article","created":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T16:16:58Z","timestamp":1459527418000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["What can we offer to 3 million MDRTB household contacts in 2016?"],"prefix":"10.1186","volume":"14","author":[{"given":"David A. J.","family":"Moore","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,4,1]]},"reference":[{"key":"610_CR1","unstructured":"Organisation WH. 2015 Global tuberculosis report. Geneva, 2015."},{"key":"610_CR2","unstructured":"Organisation WH. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva, 2014."},{"issue":"5","key":"610_CR3","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1164\/rccm.201001-0077OC","volume":"182","author":"A Deun Van","year":"2010","unstructured":"Van Deun A, Maug AK, Salim MA, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010;182(5):684\u201392.","journal-title":"Am J Respir Crit Care Med"},{"key":"610_CR4","unstructured":"Organisation WH. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis. Geneva, 2013."},{"key":"610_CR5","unstructured":"Organisation WH. The use of delamanid in the treatment of multidrug-resistant tuberculosis - interim policy guidance. Geneva, 2014."},{"issue":"9","key":"610_CR6","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.5588\/ijtld.11.0030","volume":"15","author":"L Grandjean","year":"2011","unstructured":"Grandjean L, Crossa A, Gilman RH, et al. Tuberculosis in household contacts of multidrug-resistant tuberculosis patients. Int J Tuberc Lung Dis. 2011;15(9):1164\u20139. i.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"6","key":"610_CR7","doi-asserted-by":"crossref","first-page":"e1001843","DOI":"10.1371\/journal.pmed.1001843","volume":"12","author":"L Grandjean","year":"2015","unstructured":"Grandjean L, Gilman RH, Martin L, et al. Transmission of Multidrug-Resistant and Drug-Susceptible Tuberculosis within Households: A Prospective Cohort Study. PLoS Med. 2015;12(6):e1001843. discussion e.","journal-title":"PLoS Med"},{"key":"610_CR8","unstructured":"Organisation WH. Recommendations for investigating contacts of persons with infectious tuberculosis in low- and middle-income countries. 2012."},{"key":"610_CR9","unstructured":"Organisation WH. Guidelines on the management of latent tuberculosis infection. Geneva; 2015."},{"key":"610_CR10","doi-asserted-by":"crossref","unstructured":"Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev. 2000, (2): CD001363.","DOI":"10.1002\/14651858.CD001363"},{"issue":"9777","key":"610_CR11","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/S0140-6736(11)60204-3","volume":"377","author":"T Samandari","year":"2011","unstructured":"Samandari T, Agizew TB, Nyirenda S, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;377(9777):1588\u201398.","journal-title":"Lancet"},{"issue":"14","key":"610_CR12","doi-asserted-by":"crossref","first-page":"5325","DOI":"10.1073\/pnas.1317660111","volume":"111","author":"RM Houben","year":"2014","unstructured":"Houben RM, Sumner T, Grant AD, White RG. Ability of preventive therapy to cure latent Mycobacterium tuberculosis infection in HIV-infected individuals in high-burden settings. Proc Natl Acad Sci U S A. 2014;111(14):5325\u201330.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"610_CR13","doi-asserted-by":"crossref","unstructured":"Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010, (1): CD000171.","DOI":"10.1002\/14651858.CD000171.pub3"},{"issue":"9944","key":"610_CR14","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S0140-6736(14)60162-8","volume":"384","author":"MX Rangaka","year":"2014","unstructured":"Rangaka MX, Wilkinson RJ, Boulle A, et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. Lancet. 2014;384(9944):682\u201390.","journal-title":"Lancet"},{"issue":"Suppl 5","key":"610_CR15","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1097\/01.aids.0000391022.95412.a6","volume":"24","author":"B Durovni","year":"2010","unstructured":"Durovni B, Cavalcante SC, Saraceni V, et al. The implementation of isoniazid preventive therapy in HIV clinics: the experience from the TB\/HIV in Rio (THRio) study. AIDS. 2010;24 Suppl 5:S49\u201356.","journal-title":"AIDS"},{"issue":"11","key":"610_CR16","first-page":"1320","volume":"13","author":"Y Zhang","year":"2009","unstructured":"Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 2009;13(11):1320\u201330.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"10","key":"610_CR17","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/nm1110","volume":"10","author":"T Cohen","year":"2004","unstructured":"Cohen T, Murray M. Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness. Nat Med. 2004;10(10):1117\u201321.","journal-title":"Nat Med"},{"issue":"5782","key":"610_CR18","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1126\/science.1124410","volume":"312","author":"S Gagneux","year":"2006","unstructured":"Gagneux S, Long CD, Small PM, Van T, Schoolnik GK, Bohannan BJ. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science. 2006;312(5782):1944\u20136.","journal-title":"Science"},{"issue":"3","key":"610_CR19","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/cid\/cit643","volume":"58","author":"NS Shah","year":"2014","unstructured":"Shah NS, Yuen CM, Heo M, Tolman AW, Becerra MC. Yield of contact investigations in households of patients with drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis. 2014;58(3):381\u201391.","journal-title":"Clin Infect Dis"},{"key":"610_CR20","unstructured":"Goldman JA, Kearns GL. Fluoroquinolone use in paediatrics: focus on safety and place in therapy, 2011."},{"issue":"4","key":"610_CR21","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1128\/AAC.02202-12","volume":"57","author":"J Sarathy","year":"2013","unstructured":"Sarathy J, Dartois V, Dick T, Gengenbacher M. Reduced drug uptake in phenotypically resistant nutrient-starved nonreplicating Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2013;57(4):1648\u201353.","journal-title":"Antimicrob Agents Chemother"},{"issue":"23","key":"610_CR22","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","volume":"365","author":"TR Sterling","year":"2011","unstructured":"Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155\u201366.","journal-title":"N Engl J Med"},{"key":"610_CR23","unstructured":"Seddon JA, Fred D, Amanullah F, et al. Post-exposure management of multidrug-resistant tuberculosis contacts: evidence-based recommendations. Dubai, UAE: Harvard Medical School Centre for Global Health Delivery - Dubai, 2015."}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-016-0610-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T05:26:23Z","timestamp":1567747583000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-016-0610-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,1]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["610"],"URL":"https:\/\/doi.org\/10.1186\/s12916-016-0610-x","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,1]]},"article-number":"64"}}